Last edition
News about
Otsuka receives FDA accelerated approval for Voyxact in adults with IgA nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the US FDA has granted accelerated approval for Voyxact (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
Novartis to cut 550 jobs in Switzerland as it shifts focus to cell therapy and advanced biologics
Novartis announced plans to eliminate 550 jobs in Switzerland by the end of 2027 as part of a strategic shift toward cell therapy, RNA-based medicines, and other advanced biologics. The cuts will primarily affect its Stein facility, where the company is phasing out the production of pills, capsules, and sterile medicine packaging.
Bry-Air Displays P80x at PMEC Expo 2025
Bry-Air showcased its next-generation P80x dehumidification system at PMEC Expo 2025, highlighting its superior efficiency, sustainability benefits, and performance advantages over traditional silica gel–based technologies.
Eris Lifesciences to Increase Its Stake in Swiss Parenterals
Eris Lifesciences has announced plans to consolidate its stake in Swiss Parenterals, while bringing Naishadh Shah on board as a top-10 shareholder and part of the management, strengthening its leadership and long-term strategic vision.
US FDA Approves Label Update for Sun Pharma's UNLOXCYT
Sun Pharma has received US FDA approval for a label update to UNLOXCYT, the first and only PD-L1 inhibitor for advanced Cutaneous Squamous Cell Carcinoma (aCSCC), further supporting its clinical value with durable responses and a favourable safety profile for patients with multiple comorbidities.
Eisai completes FDA submission for weekly subcutaneous LEQEMBI autoinjector
Eisai has completed the rolling submission of its Supplemental Biologics License Application (sBLA) to the US Food and Drug Administration for LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector formulation of lecanemab-irmb (LEQEMBI), following the FDA’s Fast Track designation.
Teva secures EC approval for two denosumab biosimilars, Ponlimsi and Degevma
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., has received marketing authorizations from the European Commission for its two denosumab biosimilars—Ponlimsi, referencing Prolia, and Degevma, referencing Xgeva.
CBC India Launches New 'Ingredients & Packaging Solutions' Business at CPHI India 2025
CBC India has unveiled its new ‘Ingredients & Packaging Solutions’ business at CPHI India 2025, marking a major step in its evolution toward offering integrated, end-to-end formulation and packaging support. The new identity strengthens the company’s role as a versatile, future-ready partner for pharma, nutraceutical, and allied sectors.
Sovereign Pharma Unveils India's First High-Volume Ampoule Isolator Line
Sovereign Pharma has unveiled India’s first high-volume ampoule isolator line, a state-of-the-art solution designed to deliver enhanced sterility assurance, minimise contamination risks, and meet global regulatory standards.
Biogen Inc. has entered into a research collaboration with Dayra Therapeutics to discover and develop oral macrocyclic peptides targeting high-priority immunological conditions.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy